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ABSTRACT
New therapies are needed for advanced hepatocellular carcinoma (HCC) and the 
use of mesenchymal stromal cells (MSCs) carrying therapeutic genes is a promising 
strategy. HCC produce cytokines recruiting MSCs to the tumor milieu and modifying its 
biological properties. Our aim was to study changes generated on human MSCs exposed 
to conditioned media (CM) derived from human HCC fresh samples and xenografts. All 
CM shared similar cytokines expression pattern including CXCL1-2-3/GRO, CCL2/MCP-
1 and CXCL8/IL-8 being the latter with the highest concentration. Neutralizing and 
knockdown experiments of CCL2/MCP-1, CXCL8/IL-8, CXCR1 and CXCR2 reduced in 
vitro MSC migration of ≥20%. Simultaneous CXCR1 and CXCR2 neutralization resulted in 
50% of MSC migration inhibition. MSC stimulated with CM (sMSC) from HuH7 or HC-PT-5 
showed a 2-fold increase of migration towards the CM compared with unstimulated MSC 
(usMSC). Gene expression profile of sMSC showed ~500 genes differentially expressed 
compared with usMSC, being 46 genes related with cell migration and invasion. sMSC 
increased fibroblasts and endothelial cells chemotaxis. Finally, sMSC with HuH7 CM and 
then inoculated in HCC tumor bearing-mice did not modify tumor growth. In this work we 
characterized factors produced by HCC responsible for the changes in MSC chemotactic 
capacity with would have an impact on therapeutic use of MSCs for human HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the 2nd cause 
of cancer-related death worldwide and its incidence 
is steadily increasing despite the advances in the 
understanding of hepatocarcinogenesis [1]. The vast 
majority of HCC arise in livers with underlying cirrhosis 
due to chronic hepatitis B or C virus infection or heavy 
alcohol consumption [2]. Unfortunately, most patients 
with HCC are diagnosed at advanced stages when 
curative options such as liver resection, transplantation 
or radiofrequency ablation are not feasible. Sorafenib, 
a multikinase inhibitor drug, is the standard of care for 
patients with advanced HCC, however, median overall 
survival was 10.7 months in the sorafenib group and 7.9 
months in the placebo group [3]. Therefore, development 
of new therapeutic approaches is required for HCC. In 
this scenario, cells armed with antitumor genes or carrying 
oncolytic viruses have been be proposed as therapeutic 
tools in several preclinical models [4]. In particular, 
mesenchymal stromal cells (MSCs) have shown the 
capability to migrate to tumors in vivo making them a 
promising therapeutic strategy in cancer therapy.
MSCs are a heterogeneous population of 
multipotent cells present in almost all adult tissues that 
migrate to sites of injury and have the capability to 
differentiate into mesodermal derivatives (adipocytes, 
osteoblasts and chondroblasts) [5]. In addition, MSCs 
have also shown immunoregulatory and pro-regenerative 
effects due to the secretion of several growth factors 
and cytokines [6]. MSCs are usually isolated from bone 
marrow (BM), adipose tissue or from neonatal tissues 
such as umbilical cord [7]. Tumors have been considered 
as unresolved wounds since a continuous process of 
damage and repair is taking place [8]. At least in part, 
this process is orchestrated by an extensive crosstalk 
between cancer cells and its microenvironment. In this 
context, tumor tropism of MSCs make them a potential 
tool for the development of new cancer therapies as 
carriers of oncolytic vectors or producing antitumor genes 
[4]. However, mechanisms and signals involved in their 
recruitment to the tumor are not completely elucidated. 
It is known that MSCs express several cytokines and 
chemokines receptors allowing their migration in 
response to signals released by the tumor and their 
microenvironment. It has been proposed that MSCs use 
different combination of cytokines and growth factors for 
their homing depending on the tumor type [9]. Results 
obtained from in vitro and in vivo studies identified key 
factors involved in MSC migration such as VEGF, PDGF, 
TGF-β, CCL2/MCP-1, CXCL8/IL-8, TNF-α, IL-1β, IL-
6, CXCL12/SDF-1 or HGF [10, 11]. Particularly, we 
have recently shown that MSCs migrate towards HCC, 
partially through the autocrine motility factor (AMF)/
autocrine motility factor receptor (AMFR) [12]. In 
addition, MSCs were isolated from different tumors types 
including HCC and HCC-associated MSCs have shown 
pro-tumorigenic properties demonstrating that these cells 
could be educated by the tumor [13]. Therefore, several 
aspects of MSC homing into tumors should be addressed 
before these cells can be considered for clinical purposes, 
including the evaluation of which cytokine and/or growth 
factors are released by HCC and how these factors affect 
MSC migration and its interaction with the different 
components of the entire tumor.
Here, for the first time, we report the identification 
of CXCL8/IL-8, CCL2/MCP-1, and CXCL1-2-3/GRO 
as chemotactic axis for MSC migration toward human 
HCC. We further demonstrate that HCC-stimulated 
MSCs increased their chemotactic potential and modified 
their gene profile pattern including genes involved in 
migration and invasion process. In addition, we observed 
that stimulated MSCs secreted several chemokines that 
induce the recruitment of fibroblasts, endothelial cells 
and peripheral blood mononuclear cells (PBMNCs) 
towards the HCC. Systemic administration of stimulated 
or unstimulated MSCs did not affect HCC aggressiveness 
in vivo.
RESULTS
Hepatocellular carcinoma-derived factors induce 
human MSC migration
We and others have demonstrated that MSCs 
migrate in vitro and in vivo towards HCC [14]. Recently, 
we reported that MSC in vitro migration toward HCC is 
mediated in part by AMF [12], however other cytokines 
and growth factors could also be involved. In order to 
identify factors that could mediate MSC recruitment to 
human HCC we examined the cytokine profile of different 
human HCC samples. Conditioned medium (CM) derived 
from fresh HCC patient samples (PT-7, PT-12 and PT-19) 
or from tumors induced by the inoculation of a primary 
culture from a HCC patient (HC-PT-5) or HuH7 HCC cells 
in nude mice were analyzed with a cytokine antibody array 
(Figure 1A and 1B). Quantification of arrays showed that 
all CM analyzed contain CXCL1-2-3/GRO, CCL2/MCP-
1, and CXCL8/IL-8 being the latter cytokine the most 
important (Figure 1C). Interestingly, CM derived from 
HuH7, PT-7, PT-12 and PT-19 showed high levels of IL-6 
and angiogenin while the CM from the HC-PT-5 tumor 
did not present these cytokines. Regarding CXCL7/NAP-
2 and HGF only were found in CM from HuH7 and PT-
19. We next wondered if these factors are specific for the 
tumoral tissue (TT) or if they can be found in the adjacent 
non-tumoral liver parenchyma (AT) derived from the same 
patients with HCC; primary biliary cirrhosis (PT-7) or 
cryptogenic cirrhosis (PT-12). Cytokine antibody arrays 
of AT showed that the 2 samples have a different pattern 
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Figure 1: HCC factors induce MSC in vitro chemotaxis. A. Antibody array of CM derived from subcutaneous (s.c.) tumors 
generated in nude mice using HuH7 or HC-PT-5 cells, or fresh HCC patient sample (PT-19). Pos: positive control; Neg: negative control. B. 
Antibody array of CM derived from fresh tumor tissue or non-tumoral liver parenchyma (patient samples PT-7 or PT-12). C. Quantification 
of the antibody array signal from tumoral CM by densitometry. Results are expressed as relative intensity (%); positive controls were used 
to normalize the results. D. Quantification of antibody array signal and comparison between factors present in tumoral tissue (TT) and 
non-tumoral liver parenchyma (AT) from PT-7 (upper panel) and PT-12 (bottom panel). Results are expressed as relative intensity (%). E. 
Antibody array of CM derived from LX-2 cell line (left panel) and its quantification by densitometry (right panel). Results are expressed 
as relative intensity (%) and positive controls were used to normalize the results. F. MSC in vitro chemotaxis was analyzed with a modified 
Boyden chamber assay using the previously analyzed CM as chemoattractant. Results are expressed as number of cells per field ± SEM 
from 3 independent experiments, each performed in quadruplicate. *p<0.05 and ***p<0.01 vs DMEM; σp<0.05 vs AT from the same patient 
sample (ANOVA and Dunn’s post test).
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of cytokine expression. On one hand, CM derived from 
AT-PT-7 showed higher levels of CXCL10/IP-10, TGFβ2, 
CCL17/TARC and LIF but lower levels of CXCL8/IL-8 
and CXCL1-2-3/GRO in comparison with TT (Figure 1B 
and 1D). On the other hand, CM from AT-PT-12 presented 
the expression of few factors compared to the other CM. 
Only CXCL8/IL-8, CCL2/MCP-1 and CXCL1-2-3/GRO 
were found (Figure 1B and 1D). It should be noted that 
levels of CXCL8/IL-8 and CCL2/MCP-1 were lower than 
those observed for the CM derived from the TT but the 
expression of CXCL1-2-3/GRO was higher (Figure 1D). 
The cytokine pattern was also evaluated in hepatic stellate 
cells (HSC), the main cell type involved in hepatic 
fibrogenesis. Cytokines present in the CM derived from the 
HSC cell line LX-2 were analyzed. As a result, we observed 
an expression pattern similar to AT-PT-12; in addition, IL-6 
and CXCL7/NAP-2 were also detected (Figure 1E). Then, 
we assessed if these differences affected the MSC in vitro 
chemotaxis capability. In vitro migration assays showed 
that MSCs migrate preferentially to tumor derived CM 
(Figure 1F). However, CM derived from AT-PT-12 and AT-
PT-30 were able to induce MSC migration in some degree.
CXCL8/IL-8, CXCL1-2-3/GRO and CCL2/
MCP-1 axes are important for MSC in vitro 
migration towards human HCC
CXCL8/IL-8, CXCL1-2-3/GRO and CCL2/MCP-1 
have been described as chemotactic factors for MSCs. In 
addition these cytokines were found in all the CM from 
human HCC samples. Therefore, we hypothesized that 
these chemokines could be involved in MSC chemotaxis 
toward HCC. Neutralizing antibody against CCL2/MCP-
1 reduced the capability of inducing MSC chemotaxis 
toward CM derived from the human HCC tumors HuH7, 
HC-PT-5 or PT-19 by around a 20% while the anti-HGF 
antibody did not (Figure 2A). In a similar way incubation 
of MSCs with anti-CXCR1 or anti-CXCR2 antibodies 
reduced their in vitro chemotaxis capability to HCC by 
around a 20~30%. Furthermore, when both receptors 
were neutralized together, MSC chemotaxis was reduced 
by around 50~60% (Figure 2A). The migration involving 
CXCR1 and CXCR2 was also evaluated by knocking 
down their expression in MSCs by shRNA. Two-different 
shRNAs were used for each receptor (Figure 2B). Then, 
migratory experiments showed decreased MSC migration 
of around 20~30% towards HuH7 CM compared to 
control (SCR) (Figure 2C). To further validate these 
migratory axes in MSC migration, CCL2/MCP-1 and 
CXCL8/IL-8 production was inhibited in HuH7 by siRNA. 
Two different siRNA were used for knockdown of each 
cytokine (Figure 2D). Chemotaxis experiments showed 
decreased migration of MSCs towards the HuH7 CM after 
CCL2/MCP-1 or CXCL8/IL-8 cytokine inhibition (Figure 
2E). Then, considering the key role of the HSC cells in 
liver cirrhosis and hepatocarcinogenesis, the CXCR1 and 
CXCR2 axes were studied in MSC migration to LX-2 
CM. Similarly to HCC CM samples, MSC chemotaxis 
towards LX-2 CM was decreased when CXCR1 and 
CXCR2 were blocked (Figure 2F). In our previous work 
[12] we demonstrated that the blockage of AMF decreased 
MSC migration towards HCC CM. To further analyze the 
cooperative role of several cytokines in the recruitment of 
MSCs to HCC, neutralizing experiments were performed. 
The simultaneous blockage of AMF, CXCR1 and CXCR2 
resulted in a higher decrease of MSC migration in 
comparison with AMF alone or with CXCR1 + CXCR2 
(Figure 2G).
Exposure of MSCs to human HCC conditioned 
media enhanced their migratory capacity
Taking into account that HCC released factors were 
able to induce MSC migration we investigated whether 
this capability could be enhanced by the exposure to the 
CM. With this aim, MSCs were incubated for 24 hours in 
the presence of the HuH7 or the HC-PT-5 CM. Migration 
assay showed a 2-fold increase in the migration of 
stimulated MSCs toward the CM derived from the HuH7 
or HC-PT-5 tumors in comparison with unstimulated 
MSCs (Figure 3A). Similarly, stimulation of MSCs with 
LX-2 CM also increased their migration (Figure 3A). With 
the aim of identifying the molecular pathways involved in 
this chemotactic effect, gene expression analysis of MSCs 
exposed to the CM derived from the HCC tumors (PT-7, 
PT-12, HuH7 and HC-PT-5) was performed using cDNA 
microarray. Gene expression profile showed that MSCs 
stimulated with CM from PT-7 differentially expressed 445 
genes in comparison with unstimulated cells. In a similar 
way, 511, 521 and 511 genes were differentially expressed 
after the exposure to CM derived from PT-12, HC-PT-5 
or HuH7, respectively. Overlap of transcripts modulated 
after the exposure to the different CM is shown in a Venn 
diagram in Figure 3B. Among them 46 genes related with 
cell migration and invasion toward tumors were identified. 
The overlap of the transcripts of these selected genes in 
the MSCs exposed to the different CM was depicted with 
a Venn diagram in Figure 3B. In particular, we found 
cytokines, receptors, adhesion molecules and proteases 
that modulate the extracellular matrix and their interaction 
with the cell receptors (described in Table 1). Interestingly, 
AMFR and IGFBP5 were modulated after the exposure to 
all the CM. However, validation by qPCR analysis showed 
not only these genes modulation after MSC exposure to 
the tumoral CM (Figure 3C) but also the modulation 
of CXCL1/GRO-1, CXCL6/GCP-2, CXCL12/SDF-1, 
PDGFR-A, ADAM9 and IGFBP3 (Figure 3D).
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MSCs exposed to human HCC conditioned 
medium modulated migratory capacity of other 
cell components of tumor microenvironment
Tumors and their microenvironment establish 
an extensive cross-talk that involves several cytokines 
leading to tumor growth and spread. We asked if once 
MSCs arrive to HCC could change the behavior of the 
cellular components that form the tumor milieu and if 
the effect of MSCs could depend of the exposure to the 
factors present in tumor microenvironment. With this 
aim, we performed chemotaxis assays of fibroblasts (WI-
38), peripheral blood mononuclear cells (PBMNCs) or 
endothelial cells (HMEC-1) toward conditioned media 
derived from MSCs stimulated with HuH7 CM or HC-
PT-5 CM as wells as unstimulated MSCs as control. 
Migration assay showed that WI-38 cells, PBMNCs 
and HMEC-1 cells not only were able to migrate toward 
MSCs CM but also this migration was increased when 
CM was obtained from MSCs previously stimulated with 
HuH7 or HC-PT-5 conditioned media (Figure 4A–4C). In 
order to identify which factors could be involved in this 
Figure 2: CXCL8/IL-8, CXCL1-2-3/GRO and CCL2/MCP-1 axes are important for MSC in vitro migration. A. In vitro 
chemotaxis assay of MSCs towards CM derived from HuH7 (left panel), HC-PT-5 (middle panel) or PT-19 (right panel). Pre-treatment 
with neutralizing antibodies to inhibit HGF or CCL2/MCP-1 was performed in each CM, while inhibition of CXCR1, CXCR2 or CXCR1 
+ CXCR2 was performed in MSCs. Results are expressed as percentage of control (isotype control IgG) ± SEM. *p<0.05, **p<0.01 
and ***p<0.001 vs control (ANOVA and Dunnett’s test). B. qRT-PCR analysis of CXCR1 or CXCR2 expression in MSCs 72 h after 
transduction with 2 different specific shRNAs retrovirus. Untransduced MSCs (control) and scrambled negative control (SCR) were used. 
*p<0.05 vs control and SCR (Kruskal-Wallis test). C. In vitro chemotaxis assay of CXCR1 or CXCR2 depleted MSCs towards CM derived 
from HuH7. Results are expressed as percentage of control (untransduced MSCs) ± SEM. *p<0.05, **p<0.01 and ***p<0.001 vs control 
and SCR (ANOVA and Dunnett’s test). D. qRT-PCR analysis of CCL2/MCP-1 or CXCL8/IL-8 expression in HuH7 72 h after transfection 
with specific siRNAs. Untransfected HuH7 and scrambled negative control (SCR) were used. *p<0.05 vs control and SCR (Kruskal-Wallis 
test). E. In vitro chemotaxis assay of MSCs towards CM derived from monolayer of CCL2/MCP-1 or CXCL8/IL-8 depleted HuH7 cells. 
Results are expressed as percentage of control (untransfected MSCs) ± SEM. *p<0.05 and ***p<0.001 vs control and SCR (ANOVA and 
Dunnett’s test). F. In vitro chemotaxis assay of MSCs towards CM derived from LX-2 cells. Pre-treatment with neutralizing antibodies to 
inhibit CXCR1 + CXCR2 was performed in MSCs. Results are expressed as percentage of control (isotype control IgG) ± SEM. ***p<0.001 
vs control (t-test). G. In vitro chemotaxis assay of MSCs towards CM derived from HuH7. Pre-treatment with neutralizing antibody to 
inhibit AMF was performed in the CM, while antibody inhibition of CXCR1 + CXCR2 was performed in MSCs. Results are expressed as 
percentage of control (isotype control IgG) ± SEM. ***p<0.001 vs control; Фp<0.05 vs anti-AMF and anti-CXCR1+anti-CXCR2 (ANOVA 
and Dunnett’s test). All of the above data represent the average of 3 independent experiments, each performed in quadruplicate.
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phenomenon we characterize the chemokine profile of 
the CM of MSCs stimulated with the CM of HuH7 and 
HC-PT-5. Protein array shows that the 5 most expressed 
chemokines in unstimulated MSCs CM were CCL2/MCP-
1, CXCL7/NAP-2, CXCL10/IP-10, CCL4/MIP-1β and 
CCL24/eotaxin-2 while CXCL8/IL-8, CXCL6/GCP-2 
and CXCL1-2-3/GRO were moderately expressed (Figure 
5A). Interestingly, CM derived from MSCs exposed to 
HC-PT-5 CM or HuH-7 CM have similar levels of CCL2/
MCP-1, higher levels of CXCL1-2-3/GRO, CXCL8/IL-8, 
CXCL6/GCP-2 and lower levels of CCL24/eotaxin-2 and 
CXCL7/NAP-2 in comparison of CM of unexposed MSCs 
(Figure 5A–5D). It should be noted that MSCs exposed 
to HC-PT-5 CM increased their secretion of CXCL5/
ENA-78, CCL4/MIP-1β and CCL7/MCP-3 while MSCs 
exposed to HuH7 decrease the release of CXCL10/IP-10 
(Figure 5D).
Effect of MSCs stimulated with HCC CM on 
HCC aggressiveness and survival
Finally, we decided to evaluate the effect of MSCs 
stimulated with tumor CM on tumor aggressiveness. 
For that purpose, we evaluated in vitro proliferation of 
HCC cells with the CM of MSCs stimulated with HuH7 
CM o HC-PT-5 CM. In both cases, we did not observe 
any modification in the proliferation of HuH7 or HC-
PT-5 cells (Figure 6A–6B). Next, unstimulated MSCs 
and MSCs stimulated with HuH7 CM were peritumoral 
inoculated in HuH7-bearing tumor nude mice and 
evaluated tumor progression. Consistently, we observed 
that the 3 experimental groups showed similar tumor 
growth, indicating that CM of tumor cells did not modify 
MSC function on tumor growth (Figure 6C). Importantly, 
animal survival was similar in all the experimental groups 
(Figure 6D).
DISCUSSION
Based on their capability to target sites of 
inflammation and tumors, MSCs were used as cellular 
vehicles of therapeutic genes against several types of 
tumors including HCC [15–17]. Several reports indicate 
that MSCs can promote cancer cell development and 
progression due a complex crosstalk between MSCs 
and tumor microenvironment. In fact, Yan et al. isolated 
HCC-associated MSCs from patient’s samples that 
increase tumor proliferation and invasion through the 
secretion of S1004A [18]. These results indicated that 
once MSCs home HCC are modulated through a complex 
interchange of signals. Therefore, it is necessary to 
understand how MSCs migrate and interact with HCC 
microenvironment. We and others have demonstrated 
in experimental models that systemically injected 
MSCs have preferential tropism toward HCC tumors 
in response to paracrine factors [15]. In the present 
work, we demonstrated for the first time that CXCL8/
IL-8, CXCL1-2-3/GRO and CCL2/MCP-1 are crucial 
axes for MSC migration towards HCC. The analysis of 
Figure 3: HCC CM enhanced MSC migratory capacity and induced changes in their gene expression pattern. A. 
Stimulation of MSCs with CM of HuH7 (dark grey bar), HC-PT-5 (black bar) or LX-2 (grey bar) increases chemotaxis towards CM 
derived from HuH7 or HC-PT-5 cells compared to unstimulated MSCs (DMEM, white bars). Results are expressed as percentage of control 
(DMEM) ± SEM of 3 independent experiments, each performed in quadruplicate. ***p<0.001 vs unstimulated cells (DMEM, ANOVA 
and Tukey’s comparison test). B. Venn diagram showing overlap of all the transcripts (left panel) or the genes related with cell migration 
and invasion (right panel) modulated in MSCs after the exposure to the different CM (HC-PT-5, PT-7, PT-12 or HuH7). C-D. q-RT-PCR 
validation of certain genes related with cell migration and invasion in MSCs stimulated with the CM (PT-7, PT-12, HC-PT-5 or HuH7) or 
unstimulated MSCs (DMEM). *p<0.05, **p<0.01 and ***p<0.001 vs unstimulated MSCs (DMEM, ANOVA Dunnett’s test).
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Table 1: Genes differentially expressed in MSCs stimulated with CM (PT-7, PT-12, HC-PT-5 or HuH7) in 
comparison to unstimulated MSCs
Gene Gene ID P value RE P value RE P value RE P value RE
CM PT-7 PT-12 HC-PT-5 HuH7
Cytokines CTGF 1490 0.01 1.31 0.004 1.37 n.c. n.c. n.c. n.c.
CYR61 3491 <0.001 1.78 <0.001 1.70 n.c. n.c. n.c. n.c.
TNFSF12 8742 n.c. n.c. 0.01 1.46 n.c. n.c. 0.046 1.32
CXCL1 2919 n.c. n.c. n.c. n.c. 0.006 1.97 0.012 1.85
LIF 3976 n.c. n.c. 0.01 1.38 <0.001 1.60 0.001 1.54
CSF1 1435 0.011 1.36 n.c. n.c. n.c. n.c. n.c. n.c.
MIF 4282 0.035 1.15 n.c. n.c. n.c. n.c. n.c. n.c.
PDGFC 56034 0.049 1.18 n.c. n.c. n.c. n.c. n.c. n.c.
CXCL6 6372 n.c. n.c. n.c. n.c. 0.044 1.35 n.c. n.c.
IL6 3569 n.c. n.c. n.c. n.c. 0.024 1.43 n.c. n.c.
CXCL14 9547 n.c. n.c. <0.001 0.56 n.c. n.c. 0.014 0.74
CXCL12 6387 n.c. n.c. n.c. n.c. 0.003 0.72 n.c. n.c.
Receptors AMFR 267 0.024 1.24 0.022 1.25 <0.001 1.46 0.005 1.34
TRAF7 84231 0.039 1.35 n.c. n.c. n.c. n.c. 0.029 1.37
PDGFRA 5156 n.c. n.c. n.c. n.c. 0.036 1.36 0.032 1.37
IGF1R 3480 n.c. n.c. 0.002 1.86 n.c. n.c. n.c. n.c.
TNFRSF11B 4982 n.c. n.c. 0.006 1.48 n.c. n.c. n.c. n.c.
GPR108 56927 n.c. n.c. n.c. n.c. n.c. n.c. 0.043 1.39
CD74 972 n.c. n.c. 0.042 0.79 n.c. n.c. 0.007 0.72
Proteases FURIN 5045 0.019 1.32 0.005 1.42 n.c. n.c. 0.028 1.29
ADAMTS1 9510 0.002 1.46 0.002 1.47 n.c. n.c. n.c. n.c.
MME 4311 0.009 1.26 n.c. n.c. 0.006 1.28 n.c. n.c.
FAP 2191 n.c. n.c. <0.001 1.51 n.c. n.c. 0.002 1.42
MMP3 4314 n.c. n.c. n.c. n.c. 0.035 1.32 n.c. n.c.
ADAM9 8754 n.c. n.c. 0.037 1.32 n.c. n.c. n.c. n.c.
ADAMTSL2 9719 0.039 0.81 n.c. n.c. n.c. n.c. n.c. n.c.
Adhesion
molecules CD47 961 0.024 1.43 n.c. n.c. n.c. n.c. n.c. n.c.
ITGAV 3685 n.c. n.c. n.c. n.c. 0.022 1.33 n.c. n.c.
MCAM 4162 n.c. n.c. n.c. n.c. n.c. n.c. 0.017 1.35
CDH5 1003 0.04 0.71 0.03 0.70 <0.001 0.51 0.011 0.65
(Continued )
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Gene Gene ID P value RE P value RE P value RE P value RE
CM PT-7 PT-12 HC-PT-5 HuH7
CD24 1E+08 0.005 0.73 n.c. n.c. <0.001 0.59 <0.001 0.67
CD99L2 83692 n.c. n.c. n.c. n.c. 0.008 0.80 n.c. n.c.
Signaling 
molecules GDI2 2665 n.c. n.c. n.c. n.c. 0.008 1.27 n.c. n.c.
FOS 2353 n.c. n.c. 0.003 0.72 0.004 0.72 0.001 0.70
JUN 3725 0.014 0.78 0.027 0.80 0.03 0.81 n.c. n.c.
MAPKAPK2 9261 n.c. n.c. 0.019 0.75 0.031 0.77 n.c. n.c.
CREBBP 1387 n.c. n.c. 0.013 0.75 n.c. n.c. n.c. n.c.
MAP4K3 8491 n.c. n.c. 0.025 0.80 n.c. n.c. n.c. n.c.
Kinesins KIF1B 23095 n.c. n.c. 0.004 0.72 n.c. n.c. n.c. n.c.
KIF6 221458 n.c. n.c. n.c. n.c. 0.045 0.80 n.c. n.c.
KIF1C 10749 n.c. n.c. n.c. n.c. n.c. n.c. 0.003 0.69
Membrane 
proteins CAV1 857 n.c. n.c. n.c. n.c. 0.001 0.76 <0.001 0.70
CAV2 858 n.c. n.c. n.c. n.c. 0.001 0.71 n.c. n.c.
Binding 
proteins IGFBP5 3488 0.023 0.81 <0.001 0.66 <0.001 0.65 <0.001 0.61
IGFBP3 3486 n.c. n.c. n.c. n.c. 0.004 0.73 0.009 0.76
ECM 
proteins VCAN 1462 n.c. n.c. 0.013 0.75 0.028 0.78 n.c. n.c.
RE: Relative expression compared to unstimulated MSCs
n.c.: no changes
ECM: Extracellular matrix
Figure 4: HCC CM-stimulated MSCs modulated migratory capacity of components of tumor microenvironment. 
Chemotaxis assay of fibroblasts A., peripheral blood mononuclear cells B., or endothelial cells C., towards CM of stimulated MSCs with 
HC-PT-5 (grey bars), with HuH7 (black bars) or unstimulated MSCs (DMEM, white bars). Results are expressed as percentage of control 
(DMEM) ± SEM of three independent experiments, each performed in quadruplicate. **p<0.01 and ***p<0.001 vs unstimulated MSCs 
(DMEM, ANOVA and Dunn’s post test).
Oncotarget80243www.impactjournals.com/oncotarget
CM derived from fresh human samples and from tumor 
xenografts showed a conserved pattern of cytokines and 
demonstrated high levels of these cytokines. Moreover, 
blockage or knockdown of these axes decreased MSC 
migration towards HCC CM. In our previous work, we 
found that MSCs showed an enhanced in vitro migration 
toward HCC in comparison with healthy or fibrotic 
livers [14]. Similarly, MSCs showed higher migration 
levels to HCC CM when compared with HSCs (LX-2), 
endothelial cells (HMEC-1) or fibroblast (WI-38) CM 
[14]. In line with this, in the present work we found that 
MSCs preferentially migrated in vitro toward CM derived 
Figure 5: HCC CM modulated MSC chemokine profile. Antibody array of CM from unstimulated MSCs A., HC-PT-5-stimulated 
MSCs B., or HuH7-stimulated MSCs C. D. Quantification of the antibody array signal by densitometry of CM of unstimulated MSCs (DMEM), 
HC-PT-5-stimulated MSCs (HC-PT-5) or HuH7-stimulated MSCs (HuH7). Results are expressed as relative intensity (%) and positive controls 
were used to normalize the results. *p<0.05, **p<0.01 and ***p<0.001 vs unstimulated MSCs (DMEM, ANOVA and Dunn’s post test). ND: 
non detectable.
Figure 6: HCC CM-stimulated MSCs did not modify tumor growth or animal survival. In vitro proliferation of HC-PT-5 
A., or HuH7 B., exposed to CM of unstimulated MSCs (usMSC) or CM of MSC stimulated with HC-PT-5 (HC-PT-5-sMSC) or stimulated 
with HuH7 (HuH7-sMSC). Data represent the average of three experiments. No differences in proliferation were found compared to HCC 
cells (DMEM). C. In vivo tumor growth of s.c. HuH7 tumor in nude mice (n=7/group). Seventeen days after tumor inoculation, mice were 
peritumoral administrated with unstimulated MSCs (usMSC), HuH7-stimulated MSCs (HuH7-sMSC) or vehicle (saline) as control. D. 
Survival of HuH7 tumor-bearing mice (n=7/group) administrated with unstimulated MSCs (usMSC) or HuH7-stimulated MSCs (HuH7-
sMSC). No differences in mice survival compared to control mice. Kaplan-Meier, log rank test.
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from patient tumors in comparison to those derived from 
adjacent tissue. It is worth noting that CXCL8/IL-8, 
CCL2/MCP-1 and CXCL1-2-3/GRO were also found in 
the CM of AT-PT-12 and HSCs (LX-2). However, these 
CM induced a minor chemotaxis of MSCs. Furthermore, 
CM from AT-PT-7 showed the lowest CXCL8/IL-8 
and CXCL1-2-3/GRO levels and did not induce MSC 
migration. Simultaneously blockage of CXCR1 and 
CXCR2 inhibited ~50% MSC migration. These results 
support a possible role of these cytokines in the MSC 
migration toward HCC. In line with this, a similar effect 
was observed in neutrophil migration towards CXCL8/
IL-8 and other chemokines such as CCL2/MCP-1, CCL8/
MCP-2, CCL7/MCP-3 or CXCL12/SDF-1 [19]. Recently, 
we have also demonstrated that the AMF/AMFR axis 
is, at least in part, responsible for MSC migration to 
HCC [12]. Interestingly, we observed that simultaneous 
blockage of CXCR1, CXCR2 and AMF inhibited >60% 
MSC migration. In this line, Lejmi et al. reported that 
CCL15/MIP-1 δ and CCL20/MIP-3α produced by 
HuH7 cell line are also implicated in MSC migration 
toward HCC [20]. These results are in agreement with 
the current knowledge of MSC tropism indicating that 
MSCs migrate to each tumor by a complex combination 
of different signals [9]. This effect can occur likely in a 
cooperative way allowing the cell to use its maximum 
migratory potential. Taking together these findings 
could serve to enhance MSC migration towards HCC 
microenvironment using MSCs genetically modified to 
overexpress chemokine’s receptors.
As we presume that cytokine stimulation on MSCs 
not only functions as chemotactic axis but also induces 
changes in MSCs behavior, we evaluated the effect of 
tumor CM stimulation on MSC recruitment potential. In 
this study, we demonstrated that HCC CM stimulation of 
MSCs not only increased the migratory response of MSCs 
but also induced changes in their gene expression pattern. 
We observed that CM-stimulated MSCs differentially 
expressed genes involved in several cellular processes 
including re-organization of the cytoskeleton, cell 
adhesion and extracellular matrix remodeling, required for 
migration and invasion. It should be noted that modulation 
of genes related with the AMF/AMFR chemotactic axis 
was observed after MSC exposure to the HCC CM. In 
particular, an increase in the mRNA level of AMFR 
regardless the HCC CM used was observed. Moreover, 
modulation of other genes related with the stimulation of 
this axis was observed including caveolin-1, caveolin-2, 
GDI-2, IGFBP3 and MMP-3 [12]. Together, these cell 
mediators could play a role in a positive loop to enhance 
MSC migration. In addition to the AMF/AMFR related 
genes, the modulation of additional cytokines, chemokines 
and growth factors may indicate that MSC stimulation 
with HCC CM could enhance the migratory response by 
autocrine loop stimulation or by paracrine recruitment of 
other MSCs or cellular components to the tumor milieu. 
In fact, CM generated by HCC-stimulated MSCs showed 
an increased capability to recruit fibroblasts, PBMNC 
and endothelial cells, probably due to an increase in 
chemokines such as CXCL8/IL-8, CXCL1-2-3/GRO and 
CXCL6/GCP-2.
Despite researchers efforts to elucidate the impact 
of MSCs on HCC growth and progression, there are still 
some concerns about their safety. Even founding that 
HCC-stimulated MSCs increased secretion of chemokines 
and the capability to recruit fibroblasts, PBMNC and 
endothelial cells, we did not observe any induction on 
tumor growth nor in vitro nor in vivo and the survival of 
tumor-bearing mice was similar for those inoculated or not 
with CM-stimulated MSCs. Besides the effect of MSCs 
in HCC growth and metastasis remains controversial, we 
and others have previously demonstrated the safety of 
inoculated MSCs in HCC models [12, 14, 15].
Taking together our results suggest that MSC 
migration towards HCC occurs in response to chemotactic 
axis that works in a cooperative way including CXCL8/IL-
8, CXCL1-2-3/GRO, CCL2/MCP-1 and AMF. In addition, 
the factors secreted by the HCC modulate the MSCs 
chemotactic potential and gene profile that in turn promote 
their recruitment. Moreover, HCC-stimulated MSCs could 
enhance the recruitment of other cells to the tumor milieu, 
probably through the secretion of chemokines such as 
CXCL8/IL-8, CXCL1-2-3/GRO and CXCL6/GCP-2. 
Considering that HCC-stimulated MSCs did not modify 
tumor growth, these cells can be considered for future 
HCC treatments, although methods of enhancing their 
recruitment need to be further investigated.
MATERIALS AND METHODS
Ethics statement
Animals were maintained at our Animal Resource 
Facilities (School of Biomedical Sciences, Austral 
University) in accordance with the experimental ethical 
committee and the NIH guidelines on the ethical use of 
animals. The “Animal Care Committee” from School of 
Biomedical Sciences, Austral University, approved the 
experimental protocol.
MSCs and peripheral blood mononuclear cells 
(PBMNCs) were obtained from bone marrow and whole 
blood of healthy donors after informed consent and 
protocol was approved by the “Institutional Evaluation 
Committee” (CIE) from School of Biomedical Sciences, 
Austral University (Protocol No. 12-019).
Cell lines
Human HCC cell line HuH7 were kindly provided 
by Prof. Jesus Prieto (CIMA, University of Navarra, 
Pamplona, Spain) [21]. LX-2 cell line (human HSCs 
generated by spontaneous immortalization in low serum 
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conditions) was kindly provided by Dr. Scott Friedman 
(Division of Liver Diseases, Mount Sinai School of 
Medicine, New York, USA). PT-67 retroviral packaging 
cells were obtained from Clontech. Human microvascular 
endothelial cells (HMEC-1) were from CDC (Centers for 
Disease Control, Atlanta, GA, USA) and WI-38 (human 
fibroblast cell line) was obtained from the American Type 
Culture Collection. Cell lines were cultured in complete 
DMEM (2 μM glutamine, 100 U/ml penicillin, 100 mg/
ml streptomycin) and 10% heat-inactivated fetal bovine 
serum (FBS). Primary culture of HCC cells (HC-PT-5) 
was previously generated in our laboratory and was 
cultured up to 8 passages in 70% DMEM/30% F12 culture 
medium (Invitrogen/Life Technologies) supplemented 
with 2 μM glutamine, 100 U/ml penicillin, 100 mg/
ml streptomycin and 10% FBS [14]. Peripheral blood 
mononuclear cells (PBMC) were isolated by Ficoll-Paque 
gradient resuspended in complete DMEM without FBS 
and used for experiments.
Isolation of BM-MSCs
MSCs were obtained from bone marrow of 
healthy donors (Hospital Naval Pedro Mallo, Buenos 
Aires, Argentina) and were characterized according to 
the International Society for Cellular Therapy (ISCT) 
guidelines as described previously [14].
Conditioned medium
Tumoral and adjacent tissues from patients with 
HCC were obtained at the time of surgical resection or 
liver transplantation at our institution (Austral Universitary 
Hospital, Pilar, Buenos Aires, Argentina). The project was 
approved by the “Institutional Evaluation Committee” 
(CIE) from School of Biomedical Sciences, Austral 
University (Protocol No. 11-007) and written informed 
consent was obtained from all patients.
For the generation of mice xenograft, HuH7 cells 
(2 x 106) or HC-PT-5 cells (5 x 106) were inoculated 
subcutaneously (s.c.) into the right flank of nude mice 
and dissected when tumors reached 200 mm3 in size 
approximately. In all cases the tissues were minced into 
pieces smaller than 1 mm3 and transferred to a 24-well 
tissue culture plate (6 fragments/well) with 500 μl of 
complete DMEM without FBS. After 18 h, tumor CM 
were harvested and stored at –80°C until use.
For MSC CM 1x106cells were plated in 100 mm cell 
Petri dishes. After 24 h MSCs were washed with PBS and 
cultured overnight (O.N.) with DMEM medium without 
FBS. Then MSCs were washed again with PBS and then 
stimulated with the tumoral CM or unstimulated (DMEM 
medium without FBS) for 18 h. Finally, cells were washed 
with PBS and cultured with complete DMEM without 
FBS and 18 h later, MSC CM were harvested and stored 
at –80°C until use.
For LX-2 CM, cells were cultured until reached 
90% confluence. Then cells were washed with PBS and 
cultured with complete DMEM without FBS. Eighteen 
hours later conditioned medium was harvested and stored 
at –80°C until use.
Cytokine and chemokine antibody array
The presence of soluble factors in the CM were 
detected using the RayBio Human Chemokine Antibody 
Array 1 (Cat# AAH-CHE-1) for tumoral CM and RayBio 
Human Cytokine Antibody Array 5 (Cat# AAH-CYT-5) 
for MSC CM (Ray Biotech, Inc.) according to the 
manufacturer’s protocol. The intensities of signals were 
quantified by densitometry with ImageJ software (National 
Institute of Health, USA) and positive controls were used 
to normalize the results from different membranes.
Gene knockdown with shRNA
Retroviral plasmids (pGFP-V-RS) containing 
two CXCR1 or CXCR2 specific or scrambled 
(SCR) negative control shRNAs were prepared as 
described by the manufacturer's protocol (Origene). 






(CXCR2, GI348622), and 
GCACTACCAGAGCTAACTCAGATCGTACT 
(scrambled). To produce retroviruses, PT-67 retroviral 
packaging cells (Clontech) were transfected with retroviral 
expression plasmids using Lipofectamine 2000 (Invitrogen) 
and incubated for 48 h. The culture media containing the 
retroviruses were collected and centrifuged at 2000 × g for 
5 min. Then 7.5 x 104 MSCs were seeded in 6-wells plates 
the night before and cultured with the viral stock and 4 μg/
ml polybrene. Medium was replaced 24 h after transduction 
and migration assay performed 72 h later.
Gene knockdown with siRNA
Proliferating HuH7 cells (3 x 105) were seeded into 
6-well plates and transfected with Trilencer-27 human 
siRNA against CXCL8/IL-8 (SR302384, Origene), CCL2/
MCP-1 (SR304273, Origene) or universal scrambled 
negative control (SCR) with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. 
For CM production, 96 h later cells were washed with PBS 
and cultured with complete DMEM without FBS. Eighteen 
hours later CM was harvested and stored at –80°C until use.
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In vitro migration assays
In vitro migration was performed using a 
48-Transwell microchemotaxis Boyden Chamber unit 
(Neuroprobe, Inc.) as previously described [14]. MSCs, 
WI-38 cells, HMEC-1 cells and PBMNCs (1.2 x 103 cells/
well) were placed in the upper chamber and CM was 
applied to the lower chamber of the transwell unit. For 
blocking experiments, CM or MSCs were preincubated 
for 60 min with anti-CCL2/MCP-1 (5 μg/μl), anti-HGF 
(5 μg/μl), anti-CXCR1 (5 μg/μl), anti-CXCR2 (5 μg/μl), 
anti-AMF (5 μg/μl) or isotype control IgG (5 μg/μl). For 
CM stimulation, MSCs were incubated O.N. with the CM 
or DMEM without FBS as control. The system was left 
for 4 hours at 37°C in a 5% CO2 humidified atmosphere. 
Cells attached to the lower side of the membrane were 
fixed in 2% formaldehyde, stained with 4’,6-diamidino-
2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich) 
and counted using fluorescent-field microscopy at 
100X. Captured images from three representative visual 
fields were analyzed using CellProfiler software (www.
cellprofiler.com), and the mean number of cells/field + 
SEM was calculated.
Gene expression profiling and data processing
Sample preparation
MSCs were plated at a density of 5 x 104 cells/
cm2 in 60 mm cell Petri dishes 1 day prior to assay. Then 
MSCs were washed with PBS and cultured O.N. with 
DMEM medium without FBS. Finally MSC were washed 
again with PBS and then stimulated with the tumoral CM 
or unstimulated (DMEM medium without FBS). After 
24 h, total RNA was isolated using the TRIzol reagent 
(Invitrogen) followed by purification using RNeasy mini 
kit columns (Qiagen) according to the manufacturer′s 
instructions. Then 10 μg of each RNA was subjected 
to enzymatic digestion with 1X buffer of DNAase, 2 U 
DNAse I (AmbionInc), 40 U of ribonuclease inhibitor 
(RNAaseOUT) and incubated for 30 minutes at 37°C. At 
the end of the incubation time, RNA was purified with the 
E.Z.N.A.® Total RNA Kit I (Omega Bio-Tek), following 
the supplier’s protocol. Finally, the RNA was eluted from 
the column with 20 μl of water and the quantity and 
purity of RNA determined using UV spectrophotometry 
(NanoDrop Technologies) and its integrity was verified by 
1% agarose gel electrophoresis.
Microarray labeling and hybridization
The slides used for hybridization were 48.5K Human 
Exonic Evidence Based Oligonucleotide (HEEBO) from 
Microarray Inc. (Nashville, TN, USA) based on a probe 
set designed by Illumina (San Diego, http://www.illumina.
com) and Stanford University. A detailed description of 
these arrays can be found (http://www.microarray.org/
sfgf/heebo.do). Amplification and labeling for the regular 
microarray strategy were done using the SuperScript 
Indirect RNA Amplification System (Invitrogen), following 
the supplier’s instructions. An indirect design was used for 
the hybridization of the microarray, where each aRNA from 
cells with and without treatment were labeled with Alexa 
647, was hybridized against an aRNA from a Universal 
Reference labeled with Alexa 555 (Human Universal 
Reference, Clontech). Before hybridization, the slides 
were pre-blocked with 5X SSC, 0.1% SDS and 0.1% BSA. 
Then, 60 picomoles of each fluorescent-labeled probe 
were mixed with 1X hybridization solution (5X SSC, 50% 
formamide, 0.1% SDS, and 0.01% salmon sperm DNA) 
and heated at 95°C for 2 min. After hybridization for 16 
h at 42°C, the slides were washed once in 2X SSC and 
0.1% SDS for 5 min at 42°C, washed in 2X SSC and 0.1% 
SDS for 5 min at room temperature, and washed twice with 
0.1X SSC for 1 min. Finally, the slides were centrifugally 
dried and scanned in a ScanArrayGx (PerkinElmer).
Data analysis
The signal intensity of the slides was quantified 
using the SpotReaderSoftware (Niles Scientific, USA). 
The “orange pack 1” standard and an adaptive elliptical 
circle were used to grid the image. The artifacts inside 
the glass were eliminated manually and not used in the 
analysis.
Reverse transcription-polymerase chain reaction 
(RT-PCR)
Total RNA isolated as described before (4 μg) 
was reverse transcribed with 200 U of SuperScript II 
Reverse Transcriptase (Invitrogen) using 500 ng of 
Oligo (dT) primers. cDNAs were subjected to real-
time polymerase chain reaction (qPCR) (Stratagene 
Mx3005p, Stratagene). For qRT-PCR, the mRNA levels 
of the different genes were quantified by SYBR® Green 
(Invitrogen), using the following primers: CXCR1 
forward 5’-TAAGTGGAGCCCCGTGGGG-3′ and 
reverse 5’-TTTGGATGGTAAGCCTGGC-3′; CXCR2 




AAACTTCTC-3′; CCL2/MCP-1 forward 
5’-CCACCTGGACAAGCAAACCCAA-3′ and reverse 
5’-AACAGGGTGTCTGGGGAAAGC-3′; AMFR 
forward 5’-ACAAGATGTGGGCCTTGCAAGA-3′ 
and reverse 5’-AAAACGCAGTGCTCCCAGGATA-3′; 
CXCL1/GRO-1 forward 
5’-TGAAGGCAGGGGAATGTATGTG-3′ and reverse 
5’-AGCCCCTTTGTTCTAAGCCA-3′; CXCL6/GCP-
2 forward 5’-TCAGCGGAGCAGTTTTCTGGA-3′ 
and reverse 5’-TTCAGGGAGAAGCGTAGGCTTT-3′; 
PDGFR-A forward 
5’-ACAAGCTGTATCACTGCCTTCG-3′ and reverse 
5’-AAAACATGAACAGGGGCATTCG-3′; ADAM9 




5’-GCCATGGAGGCACTAACAAACT-3′ and reverse 
5’-TTGGAACCTGAAACCCTGCTGT-3′; IGFBP3 
forward 5’-ACTGTGGCCATGACTGAGGAAA-3′ and 
reverse 5’-AGAGTCTCCCTGAGCCTGACTT-3′. PCR 
amplifications were carried out using a cycle of 95°C for 
10 min and 45 cycles under the following parameters: 
95°C for 30 seconds, 58°C for 30 seconds, 72°C for 1 
min. At the end of PCR reaction, the temperature was 
increased from 60°C to 95°C at a rate of 2°C/min, and 
the fluorescence was measured every 15 seconds to 
construct the melting curve. Values were normalized to 
levels of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; used as housekeeping) transcript (forward 
5′-CATCTCTGCCCCCTCTGCTG-3′ and reverse 
5′-GCCTGCTTCACCACCTTCTTG-3′). Data were 
processed by the ΔΔct method. The relative amount of the 
PCR product amplified from untreated cells was set as 1. 
A non-template control (NTC) was run in every assay, and 
all determinations were performed as triplicates in three 
separated experiments.
Proliferation assays
Cell proliferation was evaluated by [3H]-thymidine 
incorporation assay. Briefly, HCC cells were seeded in 96-
well culture tissue plates at 3 x 104 cells/cm2 density for 
1 day prior to the assay. Then cells were cultured with 
DMEM (control) or CM obtained from stimulated MSCs 
with the tumoral CM (HuH7 or HC-PT-5) or control 
unstimulated MSCs (culture in DMEM) for 48 h followed 
by a pulse of [3H]-thymidine 18 h before the end of the 
experiment. Finally, [3H]-thymidine incorporation was 
measured in a scintillation counter. Each sample was 
assayed in sextuplicates and normalized to DMEM as 
control.
Mice and in vivo experiments
Six- to eight-week-old male nude (Nu/Nu) mice were 
purchased from CNEA (Comisión Nacional de Energía 
Atómica, Ezeiza, Buenos Aires, Argentina). Subcutaneously 
HuH7 tumors (2 x 106 cells) were established and 17 
days later MSCs or stimulated MSCs with CM of HuH7 
were peritumoral injected. Tumor growth was assessed 
by calliper measurement, and tumor volume (mm3) was 
calculated by the formula π/6 x larger diameter x (smaller 
diameter)2.
Statistical analyses
One-way analysis of variance, Kruskal-Wallis test, 
t-test or Kaplan-Meier log rank (GraphPad Software) 
were used to statistically examine the differences between 
groups. Differences with p values lower than 0.05 were 
considered as statistically significant.
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